Oxyphenbutazone

Confirm delete?

Oxyphenbutazone

Zoom

Cat No: 18723

Biochemicals - Small Molecule Inhibitors

Oxyphenbutazone is a metabolite of phenylbutazone (Item No. 70400). Both compounds were identified as having anti-inflammatory effects in early studies, and, as a result, are considered NSAIDs.{30271} Interestingly, the effects of the two compounds in...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4-butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione

Correlated keywords:

NSAID nonsteroidal anti-inflammatory drug non-steroidal antiinflammatory tanderil p-oxyphenylbutazone organic anion transporter 1 OAT1 OAT G27202 NSC526053 Ro04-4410 Ro044410 Ro 044410

Product Overview:
Oxyphenbutazone is a metabolite of phenylbutazone (Item No. 70400). Both compounds were identified as having anti-inflammatory effects in early studies, and, as a result, are considered NSAIDs.{30271} Interestingly, the effects of the two compounds in animal models differ, with phenylbutazone having anti-inflammatory effects in rheumatic diseases and oxyphenbutazone reducing edema in certain types of acute inflammation.{30271} Oxyphenbutazone is a poor inhibitor of prostaglandin synthesis, but, like other NSAIDs, it inhibits organic anion transporter 1 (Ki = 32 µM).{30270,30268} It inhibits the growth of MH60/BSF-2 cells induced by IL-6 (IC50 = 7.5 µM).{29361} Oxyphenbutazone stimulates neurite outgrowth at 1.5 µM and sensitizes M. tuberculosis to antimicrobials.{30272,30269}

Size	1 mg
Shipping	dry ice
CAS Number	129-20-4
Molecular Formula	C₁₉H₂₀N₂O₃
SMILES	O=C(C1CCCC)N(C2=CC=CC=C2)N(C3=CC=C(O)C=C3)C1=O
Molecular Weight	324,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2907.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.